Inventory / revenue moved 896 bp lower
Inventory / revenue changed -896 basis points from the comparable as-filed period.
67.42%→58.46%2 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →ST financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Free-cash-flow margin moved 657 bp higher
Free-cash-flow margin changed +657 basis points from the comparable as-filed period.
12.25%→18.82%2 prior comparisons
Operating cash-flow margin moved 626 bp higher
Operating cash-flow margin changed +626 basis points from the comparable as-filed period.
14.94%→21.20%2 prior comparisons
Revenue increased 5.0%
Revenue changed +5.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$943.4M→$990.6M2 prior comparisons
Receivables / revenue moved 879 bp lower
Receivables / revenue changed -879 basis points from the comparable as-filed period.
83.23%→74.44%2 prior comparisons
Stock-based compensation increased 59.4%
Stock-based compensation changed +59.4% from the comparable as-filed period.
$4.5M→$7.2M2 prior comparisons
Capex / revenue moved 31 bp lower
Capex / revenue changed -31 basis points from the comparable as-filed period.
2.69%→2.38%2 prior comparisons
Inventory decreased 8.9%
Inventory changed -8.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$636.0M→$579.1M4 prior comparisons
Shares outstanding decreased 0.1%
Shares outstanding changed -0.1% from the comparable as-filed period. The change ranks at the 0th percentile of 8 prior comparable changes.
145,639,006→145,535,8628 prior comparisons
Trade receivables decreased 6.1%
Trade receivables changed -6.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$785.2M→$737.4M4 prior comparisons
Research & development decreased 2.1%
Research & development changed -2.1% from the comparable as-filed period.
$32.6M→$31.9M2 prior comparisons
Capital expenditure decreased 7.0%
Capital expenditure changed -7.0% from the comparable as-filed period.
$25.4M→$23.6M3 prior comparisons
Operating cash flow / net income decreased 11.4%
Operating cash flow / net income changed -11.4% from the comparable as-filed period.
2.32→2.061 prior comparisons
SBC / revenue moved 25 bp higher
SBC / revenue changed +25 basis points from the comparable as-filed period.
0.48%→0.73%2 prior comparisons
Current liabilities decreased 1.3%
Current liabilities changed -1.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
$827.1M→$816.5M4 prior comparisons
R&D / revenue moved 23 bp lower
R&D / revenue changed -23 basis points from the comparable as-filed period.
3.45%→3.22%2 prior comparisons
Selling, general & administrative increased 3.0%
Selling, general & administrative changed +3.0% from the comparable as-filed period.
$87.8M→$90.5M2 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.